Effects of Antioxidant Supplementation on Metabolic Disorders in Obese Patients from Randomized Clinical Controls: A Meta-Analysis and Systematic Review

Table 1

Cohen’s kappa statistics between the authors of clinical outcomes.

Outcomes	The interrater reliability		The intrarater reliability
	Pooled	95% confidence interval (CI)	Pooled	95% CI
BMI (kg/m^2)	0.62	(0.52, 0.70)	0.60	(0.55, 0.69)
WC (cm)	0.62	(0.54, 0.69)	0.59	(0.52, 0.69)
WHR (mmol/L)	0.65	(0.57, 0.73)	0.61	(0.53, 0.72)
Leptin (μg/L)	0.66	(0.54, 0.72)	0.62	(0.51, 0.68)
FM (kg)	0.55	(0.42, 0.63)	0.58	(0.51, 0.65)
FBG (μg/dL)	0.60	(0.52, 0.67)	0.61	(0.53, 0.72)
HOMAir	0.57	(0.50, 0.66)	0.59	(0.51, 0.69)
TC (μg/dL)	0.61	(0.54, 0.72)	0.59	(0.50, 0.72)
TG (μg/dL)	0.59	(0.52, 0.69)	0.60	(0.52, 0.72)
LDL (μg/dL)	0.63	(0.55, 0.70)	0.60	(0.54, 0.71)
HDL (μg/dL)	0.65	(0.53, 0.67)	0.61	(0.51, 0.70)
MDA (mmol/L)	0.66	(0.60, 0.74)	0.65	(0.55, 0.76)
SOD (mmol/L)	0.60	(0.54, 0.69)	0.61	(0.52, 0.73)
TNF‐α (pg/mL)	0.59	(0.52, 0.67)	0.59	(0.50, 0.72)
IL‐6 (pg/mL)	0.60	(0.54, 0.69)	0.62	(0.50, 0.73)
CRP (mg/L)	0.64	(0.60, 0.72)	0.65	(0.53, 0.76)
ALT (U/L)	0.65	(0.60, 0.71)	0.62	(0.52, 0.72)
AST (U/L)	0.61	(0.56, 0.70)	0.60	(0.52, 0.68)